Ticker LaunchFiled, not priced · CTY
City Therapeutics, Inc.
City Therapeutics, Inc. publicly filed a registration statement on Form S-1 on Sep 24, 2026 for a proposed initial public offering on Nasdaq Global Market under the ticker CTY, and has not yet priced. Its latest amendment was filed on Oct 9, 2026. Underwriters named in the filing: Goldman Sachs, Jefferies, Stifel and Oppenheimer.
CITY THERAPEUTICS, INC. is a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins, using its City Platform.
- Status
- Filed, not priced
- Ticker
- CTY
- Exchange
- Nasdaq Global Market
- First filed
- Sep 24, 2026
- Latest amendment
- Oct 9, 2026
- Underwriters
- Goldman Sachs, Jefferies, Stifel and Oppenheimer
- Sector
- Biotech & pharma
- Country / state
- MA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 24, 2026
- Latest amendment Oct 9, 2026
- All filings on EDGAR CIK 2143850
Other companies in the IPO pipeline
- Primagrove LtdSep 30, 2026
- TFP Group LtdSep 25, 2026
- Regenlab USA Inc.Sep 25, 2026
- Sprout Red International LtdSep 21, 2026
- NSCALE LtdSep 18, 2026
- VME Companies, Inc.Sep 18, 2026